IDH2 and neoplasm: If this is true, then any therapy that targets a driver oncogene may result in apparent tumor differentiation, as has been observed in osteogenic sarcomas following the silencing of the MYC oncogene (106) and in glioblastomas following treatment with inhibitors of mutant IDH (107).